BioXcel Therapeutics Says Deal With Teva Includes $57.5 Mln Cash, Up To $67.5 Mln Development Milestones
BTAI•Deal terms disclosed in SEC filing
Aug. 28 (Reuters) - BioXcel Therapeutics Inc. BTAI.O:
- BioXcel Therapeutics said its deal with Teva includes $57.5 million in cash, up to $67.5 million in development milestones and $20 million in commercial milestones, according to an SEC filing.
Source text: [ID:n0001104659-26-102570]
Further company coverage: BTAI.O
